Ardelyx vs Aurinia Pharmaceuticals
ARDX and AUPH side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ARDX and AUPH compare
Aurinia Pharmaceuticals is the larger company, worth 2.7 times as much as Ardelyx ($2.1B against $770M).
Aurinia Pharmaceuticals grew revenue faster over the last twelve months (21.0% versus 16.8% for Ardelyx).
Aurinia Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 97.7% compared with −12.4% at Ardelyx.
Aurinia Pharmaceuticals scores higher on the StockData Score (13 against 9 for Ardelyx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ARDX | AUPH |
|---|---|---|
| Size and price | ||
| Market cap | $770M | $2.1B |
| Share price | $3.09 | $15.73 |
| Change, 1 year | −48.8% | 1.2% |
| Change, 5 years | 209% | −44.7% |
| Beta (5Y) | 0.95 | 1.06 |
| Employees | 489 | 128 |
| StockData Score | ||
| Total score | 9 | 13 (better) |
| Valuation score | 2 | 3 (better) |
| Growth score | 3 | 3 |
| Performance score | 3 | 4 (better) |
| Health score | 1 | 3 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 6.9× |
| P/S | 1.7× (better) | 6.6× |
| P/B | 5.2× | 3.2× (better) |
| EV/EBITDA | – | 11.7× |
| FCF yield | −2.3% | – |
| Fair value | $7.50 | $41.31 |
| Margin of safety | 58.8% | 61.9% (better) |
| Growth | ||
| Revenue growth (TTM) | 16.8% | 21.0% (better) |
| Revenue growth, 5Y average | 122% (better) | 41.4% |
| Net income growth (TTM) | – | 304% |
| EPS growth (TTM) | – | 309% |
| Profitability | ||
| Gross margin | 94.4% (better) | 90.6% |
| Operating margin | −7.9% | 48.6% (better) |
| Net margin | −12.4% | 97.7% (better) |
| FCF margin | −4.0% | – |
| Return on equity | −38.6% | 61.4% (better) |
| Return on invested capital | – | 34.6% |
| Financial health | ||
| Interest coverage | −1.6× | 40.4× (better) |
| Current ratio | 3.34 | 6.12 (better) |
| Altman Z-score | −0.13 | 8.32 (better) |
| Piotroski F-score | 3 | 8 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | 3.6% |
| Shareholder yield | 0.00% | 3.6% (better) |
| Ownership | ||
| Held by institutions | 71.2% | 58.3% |
| Held by insiders | 6.9% | 17.3% |
| Insider net buying, 12 months | −$1.9M | $24.6M (better) |
| Short interest, % of float | 12.6% | 6.4% |
Go deeper
- ARDX stock overview
- ARDX income statement
- ARDX valuation and score
- AUPH stock overview
- AUPH income statement
- AUPH valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.